Trial Profile

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of MK4305 in Patients With Primary Insomnia- Study A

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 11 May 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Suvorexant (Primary)
Indications Insomnia
Focus Registrational; Therapeutic Use
Sponsors Merck & Co; Merck Sharp & Dohme; Merck Sharp & Dohme Corp.

Most Recent Events

18 Jul 2019 This trial has been completed in France, according to European Clinical Trials Database
08 Nov 2012 Results from this trial were used to support an NDA for suvorexant, which was accepted for review by the FDA in November 2012.
13 Jun 2012 Primary endpoint 'Wake-time-after-sleep-onset' has been met.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com